ALSA Ventures

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Axovia Therapeutics focuses on creating transformative therapies for ciliopathies, which are genetic disorders that can lead to severe consequences, including blindness. The company employs Adeno-Associated Virus (AAV) technology to develop gene therapies that address the underlying causes of these conditions. By targeting key aspects of ciliopathies, Axovia aims to enhance early diagnosis and treatment options, ultimately improving the quality of life for patients, their families, and caregivers affected by these rare disorders.

Vantage Biosciences is a developer of an oral therapy designed for diabetic eye diseases.

Jatri is a rapidly growing technology company based in Bangladesh, focused on providing reliable transport solutions through its mobility-as-a-service platform. The company aims to enhance the reliability and quality of the bus system, facilitating better travel experiences for commuters. By offering a platform for bus ticketing and tracking, Jatri promotes a shift from private vehicle ownership to more equitable, affordable, and accessible smart mobility options. This initiative seeks to streamline the journey experience for customers and enable drivers to deliver dependable transportation services.

Epsilogen Ltd is an immuno-oncology company based in London, United Kingdom, founded in 2016. The company specializes in developing immunoglobulin E (IgE) antibodies aimed at treating cancer. Epsilogen offers a portfolio of IgE candidates that specifically target cancer antigens such as HER2, EGFR, and PD-L1. Its innovative IgE platform supports the development and validation of novel antibodies, allowing for enhanced potency, improved tumor access, and a prolonged presence in tissue. This focus on IgE-based therapies positions Epsilogen to provide effective treatment options for patients with solid tumors.

Promatix is a biotechnology company focused on developing innovative therapeutics, specifically targeting cancer treatment. The company utilizes a multi-omics platform that encompasses proteomic, genomic, and transcriptomic data to discover and validate new therapeutic targets. By analyzing differential protein expression in both diseased and normal tissues, Promatix aids medical companies in identifying potential drug targets at a protein level. Their proprietary technology, TxPro, enhances the validation process, contributing to the development of effective cancer treatments. Through these efforts, Promatix aims to advance the field of oncology by providing novel solutions for drug development.

Montis Biosciences is a biotechnology company based in Meise, Belgium, established in 2020. It focuses on developing immune-oncology therapeutics that address the relationship between vascular dysfunction and immune suppression in the treatment of solid tumors. The company has developed a target screening and assay platform that explores the interactions between tumor endothelial cells and perivascular macrophages. By understanding these cellular interactions, Montis Biosciences aims to create novel therapeutic strategies that enhance immune reactions against solid tumors, offering a new perspective for targeted cancer treatment.